K. Cunningham

Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cells

Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, James N. Gerson et autres

Introduction: High dose chemotherapy/autologous stem cell transplantation (ASCT) and CD19-directed chimeric antigen receptor-modified T cells (CART19) are potentially-curative treatment options for patients (pt) diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) and high grade B cell lymphoma (HGBL). Analysis of …

us (code pays fourni par la source)

Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphoma

Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster et autres

Introduction: Per the CORAL study, response to salvage immunochemotherapy (IC) for patients (pts) diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) and high grade B cell lymphoma (HGBL) was predicted by time to relapse, International Prognostic Index (IPI) score and …

us (code pays fourni par la source)

Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis

Susan R. Kahn, Jim A. Julian, Clive Kearon, Chu‐Shu Gu et autres

ca, us, pl (code pays fourni par la source)

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen

Aziz Nazha, Richard J. Cook, Dan T. Vogl, Patricia Mangan et autres

us (code pays fourni par la source)

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Rebecca L. Olin, Dan T. Vogl, David Porter, Selina M. Luger et autres

us (code pays fourni par la source)

Lenalidomide and stem cell collection in patients with multiple myeloma

Richard J. Cook, DT Vogl, Patricia Mangan, K. Cunningham et autres

8547 Background: Lenalidomide is an active agent for intial treatment of multiple myeloma. Autologous stem cell transplant (ASCT) as part of first line therapy has been shown to prolong survival. Marrow suppression from lenalidomide may reduce the ability to adequately collect stem …

Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Onikepe Adegbola, C. Andreadis, S. J. Schuster, Elise A. Chong et autres

8122 Background: First-line chemotherapy cures ∼50% of pts with DLBCL, while salvage therapy followed by ASCT can cure another ∼30%. R significantly improves response rates to 1st line therapy. This retrospective study was designed to test the hypotheses that: 1) ASCT is …

us (code pays fourni par la source)

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

Charalambos Andreadis, Steve Schuster, E A Chong, Jakub Svoboda et autres

us (code pays fourni par la source)

Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma

Rebecca L. Olin, Selina M. Luger, David Porter, Stephen J. Schuster et autres

High-dose melphalan followed by ASCT is a common component of the early treatment for multiple myeloma. Daily subcutaneous injections of filgrastim (Neupogen) at 5 μg/kg/day until ANC> 500/μL are routinely administered at our center from day +4 following ASCT, to accelerate hematopoietic …

us (code pays fourni par la source)